Kailera Therapeutics indicated to open at $24, IPO priced at $16

Kailera Therapeutics (KLRA) priced 39.06M shares at $16.00. The deal size was increased to 39.06M shares from 33.3M and priced at the high end of the $14.00-$16.00 range. JPMorgan, Jefferies, Leerink, TD Cowen and Evercore ISI are acting as joint book running managers for the offering. Kailera is an advanced clinical-stage biotechnology company that says it is “focused on elevating the next era of obesity care.”